What is the clinical evidence from this study?

Study design: Review. Population: Heparin-induced thrombocytopenia (HIT) and unstable angina. Intervention: Recombinant hirudin (lepirudin).

What does this research mean for the field?

Recombinant hirudin, specifically lepirudin, is an established treatment for heparin-induced thrombocytopenia and demonstrates potential clinical utility in managing unstable angina and acute coronary syndromes. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This review aims to summarize the clinical applications and pharmacological properties of recombinant hirudin, focusing on its use in heparin-induced thrombocytopenia and unstable angina.

July 20, 2026Circulation

Recombinant Hirudin in Clinical Practice

View Full Paper

Ask AI

Bookmark

Key result

Recombinant hirudin treats heparin-induced thrombocytopenia and shows potential for unstable angina and acute coronary syndromes.

Why the study?

Clinical applications for recombinant hirudins have been investigated for 10 years, with lepirudin approved for heparin-induced thrombocytopenia and under study for unstable angina, while data for rare indications remain lacking.

Design

Review

Authors

AGAndreas GreinacherUniversità Cattolica del Sacro Cuore NLNorbert LübenowUppsala University Hospital

Discussion

Member takes

Implication

Reinforces lepirudin for HIT; leaves open its role in unstable angina and ACS pending prospective trials.

Key Points

This review aims to summarize the clinical applications and pharmacological properties of recombinant hirudin, focusing on its use in heparin-induced thrombocytopenia and unstable angina.
Overview of clinical applications of lepirudin based on past research over the last 10 years
Discussion of pharmacology associated with lepirudin
Summary of indications including rare cases such as extracorporeal circulation
Lepirudin is approved for the treatment of heparin-induced thrombocytopenia (HIT).
Recent trials support the efficacy of lepirudin in patients with unstable angina, possibly indicating a new treatment option.
Limited data is available for lepirudin's use in extracorporeal circulation.

Structured PICO

Population

Patients with heparin-induced thrombocytopenia (HIT), unstable angina, or acute coronary syndromes

Intervention

Recombinant hirudin (lepirudin)

This review outlines the established role of lepirudin in treating heparin-induced thrombocytopenia and discusses its potential utility in managing acute coronary syndromes.

Limitations

Comprehensive data are lacking for rare indications such as extracorporeal circulation.

Cite This Study

Greinacher et al. (2001) conducted a review in Heparin-induced thrombocytopenia (HIT) and unstable angina. Recombinant hirudin (lepirudin) was evaluated. Recombinant hirudin (lepirudin) is an established treatment for heparin-induced thrombocytopenia and demonstrates potential clinical applications in unstable angina and acute coronary syndromes.

synapsesocial.com/papers/6a5e90cf914239cb899c1e12 https://doi.org/10.1161/01.cir.103.10.1479

View Full Paper

Ask AI

Bookmark

Recombinant Hirudin in Clinical Practice

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Recombinant Hirudin in Clinical Practice

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider